July 13 (Reuters) - Teva Pharmaceutical Industries Ltd
said on Wednesday it expected its $40 billion deal to
buy Allergan Plc's generics business to close "any
time," even as the companies extended the deadline for
completing the transaction to October to allow more time for
U.S. antitrust approval.
Read more
No comments:
Post a Comment